AstraZeneca (AZN) Tops Q1 EPS by 110c; reaffirms guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line
April 25, 2024 5:50 AM EDTAstraZeneca (NASDAQ: AZN) shares rose 5.1% in London trading Thursday after the drugmaker smashed analyst expectations for Q1 earnings and revenue.
The company posted earnings per share (EPS) of $2.06, beating the consensus estimates of $1.10. Revenue stood at $12.68 billion, also above the estimated $11.79... More
